SCHEMBL385214

SCHEMBL385214

[CH2]CCCCCCCCCCCCC(C)NC

nearest known ligand 0.37

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ADH1B P00325 1/20 0.34
ADH1C P00326 1/20 0.34
ADH1A P07327 1/20 0.34
ADH4 P08319 1/20 0.34
ADH7 P40394 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL387645 1.00 ADH1B (0.34) ADH1BADH1CADH1AADH4ADH7
SCHEMBL386695 1.00 ADH1B (0.34) ADH1BADH1CADH1AADH4ADH7
SCHEMBL387348 0.97
SCHEMBL386811 0.90
SCHEMBL11510560 0.87 ADH1B (0.41) ADH1BADH1CADH1AADH4ADH7
SCHEMBL27599967 0.84
SCHEMBL20376405 0.79 LMNA (0.46) ADH1BADH1CADH1AADH4ADH7
SCHEMBL22682128 0.79 LMNA (0.46) ADH1BADH1CADH1AADH4ADH7
SCHEMBL385684 0.78
SCHEMBL23340664 0.77 ADH1B (0.56) ADH1BADH1CADH1AADH4ADH7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101650-B2 Method for treating a immunology-related disease DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-24 US disclosed
US-8067396-B2 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2011-11-29 US disclosed
US-7910617-B2 Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound SANKYO COMPANY, LIMITED (JP) 2011-03-22 US disclosed
CN-1921847-B Amino alcohol compound SANKYO CO 2010-06-16 CN disclosed
US-20100035842-A1 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2010-02-11 US disclosed
US-20090326038-A1 Method for treating a immunology-related disease SANKYO COMPANY, LIMITED (JP) 2009-12-31 US disclosed
US-7638551-B2 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2009-12-29 US disclosed
EP-1471054-B1 AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE DAIICHI SANKYO CO LTD (JP) 2009-07-01 EP disclosed
CN-100415735-C Amino alcohol derivatives SANKYO CO (JP) 2008-09-03 CN disclosed
CN-100406437-C Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing them SANKYO CO (JP) 2008-07-30 CN disclosed
US-6964976-B2 Amino alcohol derivatives SANKYO COMPANY, LIMITED (JP) 2005-11-15 US disclosed
CN-1680563-A Amino alcohol derivatives SANKYO CO (JP) 2005-10-12 CN disclosed
CN-1630635-A Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these SANKYO CO (JP) 2005-06-22 CN disclosed
US-20050043386-A1 Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these SANKYO COMPANY, LIMITED (JP) 2005-02-24 US disclosed
EP-1471054-A1 AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE Sankyo Company, Limited (JP) 2004-10-27 EP disclosed
US-20040132784-A1 Amino alcohol derivatives SANKYO COMPANY, LIMITED (JP) 2004-07-08 US disclosed
CN-1494540-A Amino alcohol derivatives ������������ʽ���� 2004-05-05 CN disclosed
US-6723745-B2 PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASE IN WARM BLOODED ANIMAL SANKYO COMPANY, LIMITED (JP) 2004-04-20 US disclosed
US-20030236297-A1 Amino alcohol derivatives SANKYO COMPANY, LIMITED (JP) 2003-12-25 US disclosed
EP-1300405-A1 AMINO ALCOHOL DERIVATIVES Sankyo Company, Limited (JP) 2003-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236297-A1 Amino alcohol derivatives CD4, ADH1C, ADH1A ADH1B 427/4885ADH1C 2/4885ADH1A 3/4885
US-20050043386-A1 Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these PHOSPHO1, CD4, FCGRT ADH1B 634/4885ADH1C 12/4885ADH1A 6/4885
US-20040132784-A1 Amino alcohol derivatives CD4, ADH1C, ADH1A ADH1B 427/4885ADH1C 2/4885ADH1A 3/4885
US-20090326038-A1 Method for treating a immunology-related disease C3AR1, HRH3, HRH2 ADH1B 2396/4885ADH1C 1080/4885ADH1A 2605/4885
US-20100035842-A1 Amino alcohol compounds or phosphonic acid derivatives thereof PHOSPHO1, ADH1C, ADH1A ADH1B 626/4885ADH1C 2/4885ADH1A 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.